Gilead Sciences

Gilead Sciences, Inc.
	Headquarters in Foster City
Company type	Public
Traded as	Nasdaq: GILD; Nasdaq Biotechnology component; Nasdaq-100 component; S&P 100 component; S&P 500 component;
Industry	Pharmaceutics; Biotechnology;
Founded	June 22, 1987; 37 years ago
Founder	Michael L. Riordan
Headquarters	Foster City, California, United States
Area served	Worldwide
Key people	Daniel O'Day (chairman and CEO); Andrew Dickinson (CFO); Tomáš Cihlář (vice president, and senior director, Biology);
Products	AmBisome; Atripla; Biktarvy; Complera; Cayston; Descovy; Emtriva; Epclusa; Genvoya; Harvoni; Hepsera; Letairis; Lexiscan; Macugen; Odefsey; Ranexa; Sovaldi; Stribild; Tamiflu; Truvada; Tybost; Veklury; Vemlidy; Viread; Vosevi; Yescarta; Zydelig;
Revenue	US$27.12 billion (2023)
Operating income	US$7.605 billion (2023)
Net income	US$5.613 billion (2023)
Total assets	US$62.13 billion (2023)
Total equity	US$22.83 billion (2023)
Number of employees	c. 18,000 (2023)
Website	gilead.com
	Footnotes / references;

Gilead Sciences, Inc. (/ˈɡɪliəd/) is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.

Gilead was founded in 1987 under the name Oligogen by Michael L. Riordan. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs like Tamiflu and Vistide that decade.

In the 2000s, Gilead received approval for drugs including Viread and Hepsera, among others. It began evolving from a biotechnology company into a pharmaceutical company, acquiring several subsidiaries, though it still relied heavily on contracting to manufacture its drugs.

The company continued its growth in the 2010s. However, it came under heavy scrutiny over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world.^[2]^[3]^[4]^[5]^[6]

^ "Gilead Sciences, Inc. 2023 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. February 23, 2024.
^ Cite error: The named reference WSJ2019 was invoked but never defined (see the help page).
^ Cite error: The named reference Stanton2 was invoked but never defined (see the help page).
^ Cite error: The named reference Silverman was invoked but never defined (see the help page).
^ Cite error: The named reference Bloomberg2015 was invoked but never defined (see the help page).
^ Cite error: The named reference WaPo2019a was invoked but never defined (see the help page).

[10-K_2023-1] "Gilead Sciences, Inc. 2023 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. February 23, 2024.

[WSJ2019-2] Cite error: The named reference WSJ2019 was invoked but never defined (see the help page).

[Stanton2-3] Cite error: The named reference Stanton2 was invoked but never defined (see the help page).

[Silverman-4] Cite error: The named reference Silverman was invoked but never defined (see the help page).

[Bloomberg2015-5] Cite error: The named reference Bloomberg2015 was invoked but never defined (see the help page).

[WaPo2019a-6] Cite error: The named reference WaPo2019a was invoked but never defined (see the help page).

[1]

[2]

[3]

[4]

[5]

[6]